Overview

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celgene Corporation

Treatments:

Epoetin Alfa
Lenalidomide
Thalidomide